Pharmacological (Drug) Trials

Evoke and Evoke Plus

This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer’s disease. Participants will either get semaglutide or placebo (a “dummy” medicine which does not contain any study medicine) – which treatment participants get is decided by an equal chance. The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10 of the clinic visits participants will have blood samples taken. Participants must have a study partner, who is willing to take part in the study.

Trial Status: Recruitment closed
Sponsor: Novo Nordisk
Stage of Dementia: Early Alzheimer’s Disease / Mild Cognitive Impairment
Age: 55 – 85 years
Length of Trial: 3 years and 4 months
Site Locations in Ireland

Non-Pharmacological (Non-Drug) Trials

Neurostimulation study investigating memory in amnestic Mild Cognitive Impairment (aMCI)

Researchers from Trinity College Dublin are investigating if neurostimulation can modify memory performance in individuals diagnosed with amnestic Mild Cognitive Impairment (aMCI). The study is supported by Trinity College Institute of Neuroscience, The Global Brain Health Institute (GBHI), and The Alzheimer’s Association. This clinical study will involve participants completing a word-learning task whilst non-invasive neural stimulation is applied to the head.

Trial Status: Open to Recruitment
Stage of Dementia: Early Alzheimer’s Disease / Mild Cognitive Impairment
Length of Study: Participation in this study involves 3 visits over the course of 28 days.
Age: Aged 50 years or older
Site Location: Trinity College Dublin
For more information

Sense-Cog Residential Care

Many Residents with Dementia (RwD) who live in nursing homes have significant hearing and/or vision loss. Often unrecognised and unaddressed, poor sensory function can significantly worsen their quality of life by making communication more difficult and increasing confusion.

SENSE-Cog Residential Care is a feasibility  study of a sensory support intervention for RwD with hearing and/or vision loss that will test the feasibility of:

  • Screening RwD for hearing and vision loss and correcting deficits with hearing aids and glasses
  • Supporting RwD to use their hearing aids and glasses
  • Making the nursing home environment more sensory friendly
  • Improving care pathways with external hearing and vision care providers

If successful, this pilot study will be followed by a full-scale randomised controlled trial to test if this intervention can improve quality of life and other key outcomes for this population.

Trial Status: In set-up
Stage of Dementia: Mild to Moderate Dementia
Length of Study: 6 months
Age: 60 years or above
For more information